COVID-19: FUJIFILM signs contract with VLP Therapeutics: Vaccine manufacturing contract
-Manufacturing contract using drug delivery system technology-
VLP Therapeutics:
We applied for the national research and development corporation AMED / publicly offered vaccine development (second public offering) for vaccine development in Japan.
In August 2020, the development of VLP Therapeutics’ next-generation COVID-19 vaccine was adopted as a research and development agenda.
Development of next-generation vaccine:
National Center for Global Health and Medicine,
National Institute of Biomedical Innovation, Health and Nutrition,
With Oita University and Osaka City University
We plan to jointly develop the next-generation COVID-19 vaccine.
FUJIFILM [Japan]
https://www.fujifilm.com/jp/ja/news/list/5493
Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics,
for a COVID-19 Vaccine Formulation
TOKYO, October 1, 2020—
FUJIFILM Corporation
has announced the conclusion of a manufacturing contract agreement with biotechnology company VLP Therapeutics Japan LLC regarding a COVID-19 vaccine formulation developed by VLP Therapeutics.
VLP Therapeutics’ COVID-19 vaccine
is a self-amplifying (replicon) RNA*1vaccine that uses a formulation (lipid nanoparticle)*2, which is a type of Drug Delivery System (DDS) technology*3.
Fujifilm
will utilize its manufacturing facilities and infrastructure for lipid nanoparticle to handle operations relating to VLP Therapeutics’ COVID-19 vaccine formulations, from process development to manufacturing for clinical trials.
VLP Therapeutics is the Japanese subsidiary of VLP Therapeutics, LLC, a U.S. biotechnology company engaged in the development of next-generation COVID-19 vaccines, aiming to prevent infections for which no effective treatment methods exist.
Research
is currently under way at VLP Therapeutics LLC to produce next-generation COVID-19 vaccines that can, by using replicons, demonstrate a high amount of efficacy even with inoculation in small amounts, reduce the risk of adverse reactions, and cope with some genetic mutation.